Cancer Medicine Price: The National Pharmaceutical Pricing Authority (NPPA) has released a list of revised prices for 543 brand names of cancer-related drugs. The maximum retail price (MRP) of these drugs has been revised. The new prices will be effective from November 9, 2026. The authority stated that this list will be updated regularly.
This list has been released under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It includes information provided by companies until October 27, 2026. The list will be further updated upon receipt of revised prices of non-scheduled anti-cancer drugs.
Check the New Rates
Several pharmaceutical companies have announced significant price reductions for medicines used in cancer treatment. The revised prices show substantial decreases across nine medicines.
RPG Life Sciences Ltd’s Anastrozole, sold under the brand name Energol, has seen its price drop from Rs 695.76 to Rs 73.00. Dr. Reddy’s Laboratories Limited’s Azacitidine, marketed as Azacetin, has been reduced from Rs 6,337 to Rs 1,495.04.
Abbott Healthcare Pvt Ltd’s Bevacizumab, listed under the brand name “stupid” in the provided data, has fallen from Rs 21,767.70 to Rs 5,930.13. Natco Pharma Limited’s Dasatinib, sold as Dasnat 20, has decreased from Rs 2,812.50 to Rs 1,085.93.
RPG Life Sciences Ltd has also reduced the price of Denosumab, marketed as Dabrumab 60 mg, from Rs 22,031.25 to Rs 5,941.00, and Enzalutamide, sold under the brand name Annut, from Rs 6,578.20 to Rs 2,232.00.
Meanwhile, Neon Laboratories Ltd’s Erlotinib, branded as Erlib, has dropped from Rs 4,637.45 to Rs 2,008.00. Hetero Healthcare Ltd’s Fludarabine, marketed as Fludanox, has decreased from Rs 14,235 to Rs 2,432.00. RPG Life Sciences Ltd’s Fulvestrant, sold as Fulbric, has also seen a reduction from Rs 26,072.16 to Rs 5,491.00.
These listed price changes represent substantial reductions in the cost of several medicines. However, the applicable prices, pack sizes and effective dates should be verified against the official notification before publication. The brand name listed as “stupid” for Bevacizumab should also be checked, as it may contain a spelling error.